Cogstate Limited

Equities

CGS

AU000000CGS8

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 02:10:53 2024-05-16 EDT			5-day change	1st Jan Change
1.25 ^AUD	-3.10%		-8.09%	-13.49%

04-01	Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	MT
02-22	Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8%	MT

Cogstate Limited Provides Revenue Guidance for the Second Half of Fiscal Year Ending 30 June 2023

February 23, 2023 at 05:07 pm

Cogstate Limited provided revenue guidance for the second half of fiscal year ending 30 June 2023. For the second half of fiscal year 2023 revenue expected to increase over first half of fiscal year 2023.

Latest news about Cogstate Limited

Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	04-01	MT
Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8%	02-21	MT
Cogstate Limited authorizes a Buyback Plan.	02-21	CI
Transcript : Cogstate Limited, H1 2024 Earnings Call, Feb 22, 2024	02-21
Cogstate Limited announces an Equity Buyback for 5,000,000 shares, representing 2.92% of its issued share capital.	02-21	CI
Cogstate Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-21	CI
Cogstate Ends Share Buyback Program	12-04	MT
Cogstate Limited's Equity Buyback announced on February 28, 2023 has closed with 3,753,218 shares, representing 2.17% for AUD 5.59 million.	12-03	CI
Tranche Update on Cogstate Limited's Equity Buyback Plan announced on February 28, 2023.	12-03	CI
Transcript : Cogstate Limited - Special Call	23-10-12
Cogstate Joins Forces to Establish Dementia Insurance in Japan	23-09-28	MT
Cogstate Limited Announces Change of Registered Office and Principal Place of Business	23-09-12	CI
Cogstate Limited Provides Revenue Guidance for 2024	23-08-21	CI
Transcript : Cogstate Limited, 2023 Earnings Call, Aug 22, 2023	23-08-21
Tranche Update on Cogstate Limited's Equity Buyback Plan announced on February 28, 2023.	23-08-21	CI
Cogstate Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-21	CI
Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023	23-05-09	CI
Cogstate Limited Appoints Kristi Geddes as Company Secretary	23-04-27	CI
Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023	23-04-16	CI
Cogstate Limited Reports Revenue Results for the Quarter and Year to Date Ended 31 March 2023	23-04-16	CI
Transcript : Cogstate Limited, H1 2023 Earnings Call, Feb 28, 2023	23-02-27
Cogstate Limited authorizes a Buyback Plan.	23-02-27	CI
Cogstate Limited announces an Equity Buyback for AUD 13 million worth of its shares.	23-02-27	CI
Cogstate Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Cogstate Limited Revises Earnings Guidance for the Fiscal Year Ending 30 June 2023	23-02-23	CI

Chart Cogstate Limited

Duration

Period

More charts

Company Profile

Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Cogstate Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.25 AUD

Average target price

1.8 AUD

Spread / Average Target

+44.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COGSTATE LIMITED	-13.49%	147M
MODERNA, INC.	+33.37%	49.46B
IQVIA HOLDINGS INC.	+1.55%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	18.64B
BIO-TECHNE CORPORATION	+7.36%	13.16B
MEDPACE HOLDINGS, INC.	+28.30%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.1B

Other Biotechnology & Medical Research